Adcendo

Executive Summary

Adcendo ApS is a global clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, MA. The company is dedicated to developing highly differentiated first- and best-in-class antibody-drug conjugates (ADCs) for the targeted treatment of cancers with high unmet medical need. By leveraging a deep understanding of novel target biology and optimized linker-payload technologies, Adcendo aims to address tumors that are resistant to standard therapies. The company's lead ADC program is currently in Phase 1/2 clinical trials, targeting a novel antigen overexpressed in multiple solid tumors. Adcendo's proprietary platform enables the design of ADCs with enhanced therapeutic index, stable linkers, and potent payloads, positioning it to potentially become a leader in the next wave of ADC innovation. Adcendo's strategy focuses on pursuing high-value targets that are not addressed by existing ADCs, thereby offering significant differentiation. The company has built a robust pipeline of preclinical assets targeting various oncology indications. With strong scientific leadership and a growing clinical data set, Adcendo is poised to deliver meaningful results for patients. The biotech sector continues to show strong interest in ADC platforms, and Adcendo's unique approach and early clinical progress make it an attractive candidate for potential partnerships or further investment. The company's ability to execute on its clinical milestones and demonstrate proof-of-concept in its lead program will be critical for its near-term success.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 dose escalation data for lead ADC program60% success
• 2027IND submission for second ADC candidate70% success
• TBDPotential strategic partnership or licensing deal50% success